Skip to main content

Table 2 Adverse events summary (safety population)

From: Efficacy and safety of evogliptin in the treatment of type 2 diabetes mellitus in a Brazilian population: a randomized bridging study

 EVO 2.5 mg (N = 35)EVO 5 mg (N = 36)EVO 10 mg (N = 36)SITA 100 mg (N = 39)
Subjects with at least 1 AE
 N (%)23 (65.7)24 (66.7)21 (58.3)20 (51.3)
 90% CI50.5 78.951.7 79.543.3 72.337.1 65.3
Discontinuations due to AEs
 N (%)2 (5.7)1 (2.8)0 (0.0)1 (2.6)
Reported AEs
 N40494139
AEs relateda to study treatment
 N0407
SAEs
 N1111
Deaths
 N0000
  1. AE adverse event, 90% CI 90% confidence interval, EVO evogliptin, SAE serious adverse event, SITA sitagliptin
  2. aPossibly or probably related to the study treatment